Crocs, Inc. (CROX): An Undervalued Shoe Company

Page 1 of 2

Crocs, Inc. (NASDAQ:CROX) is a company which grew its revenue from just $1 million in 2003 to $847 million by 2007 on the back of an unorthodox footwear product. I’m talking about the original Crocs, Inc. (NASDAQ:CROX) shoe, which looks like this:

This fantastical growth caused the stock to skyrocket, hitting a peak in 2008 of about $72 per share. This was about 36 times 2007 earnings, suggesting that the market believed that strong growth would continue.

But after seeing 138% revenue growth the year before sales decreased in 2008 by 15% and decreased again in 2009, a combination of the financial crisis and the fad-like nature of the product being the culprits. The stock plummeted.



CROX data by YCharts

Since then the company has greatly diversified its product line, adding styles which don’t look as ridiculous as the original, and was able to grow revenue by 12% in 2012.

Gross margin has recovered nearly to the pre-crisis levels and both net income and free cash flow have turned strongly positive. Now that the stock trades at about $15 per share, is Crocs a good value?

Strong balance sheet

At the end of 2012 Crocs had $294 million in cash and only $10 million in debt and capital leases, leaving a net cash position of $284 million. This is about $3.16 in cash per share, which represents a little over 20% of the total market capitalization. This means that the market is valuing all of Crocs, Inc. (NASDAQ:CROX) future profits at about $12 per share.

Crocs, Inc. (NASDAQ:CROX) has been using some of this cash to buy back shares, with 1.9 million shares repurchased since November 2012 and 3.4 million shares remaining on its share repurchase authorization. This most recent burst in buybacks followed a steep drop in the share price, leading me to believe that the company is tactically buying back shares at low prices. Many companies overpay for their own shares, but it looks like Crocs has avoided that trap.

Profitability

EPS became turned positive in 2010 and has almost doubled in the two years since, growing from $0.76 per share to $1.44 per share in 2012. EPS growth grew by 16% in 2012 to $1.44 per share, leading to an adjusted P/E ratio of about 8.33 (after subtracting net cash from the market cap).

Instead of using net income for valuation purposes in many cases I prefer to look at owner earnings. This is similar to free cash flow but removes the effects of fluctuating working capital, which can cause the FCF to be extremely volatile. Owner earnings have grown from $73 million in 2010 to $107 million in 2011 and $137 million in 2012. On a per-share basis the 2012 value is $1.52, slightly higher than EPS and significantly higher than the free cash flow. This puts the adjusted Price/Owner Earnings ratio at about 7.9.

Data from Morningstar

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!